sars-cov2-ctls
Cell therapyexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 15, 2021 (NCT04896606)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04896606 | Phase 1/Phase 2 (Phase 2) | Jun 15, 2021 | Medical College of Wisconsin, New York Medical College, Ohio State University, University of Pennsylvania |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medical College of Wisconsin | Academic/Hospital | 1 | 0 | 1 | 2021 |
| New York Medical College | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1